SCD1 inhibitor-3
Cat. No.: DC45584
Featured
Chemical Structure
1282606-48-7
We are official vendor of:
More than 5000 active chemicals with high quality for research!
Field of application
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer.
| Cas No.: |
1282606-48-7 |
| Chemical Name: |
SCD1 inhibitor-3 |
| SMILES: |
O=C(C1=NNC(N2C=NN(CC3=CC=C(F)C=C3)C2=O)=C1)NCC4=CC=CN=C4 |
| Formula: |
C19H16FN7O2 |
| M.Wt: |
393.37 |
| Purity: |
>98% |
| Sotrage: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer[1]. |
| Target: |
SCD1[1] |
| In Vivo: |
SCD1 inhibitor-3 (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 %[1]. SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index[1]. Animal Model: Lewis rats Dosage: 5 mg/kg Administration: P.o.; 4 hours Result: Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. Animal Model: Lewis rats Dosage: 2~10 mg/kg Administration: P.o.; 4 hours Result: A dose-responsive reduction of plasma triglycerides desaturation index. |
| References: |
[1]. Sun S, et al. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors. Bioorg Med Chem. 2015;23(3):455-465. |
MSDS
| TITLE |
DOWNLOAD |
| MSDS_29311_DC45584_1282606-48-7 |
|
COA
| LOT NO. |
DOWNLOAD |
|
|
Get Quote
